In this proof-of-concept pilot study, an MLH1-immunostained TMA of cores of inflammatory bowel disease-associated colorectal cancers, we demonstrate that QuPath can be trained using a small tissue cohort to identify tissue histopathological diagnostic patterns and MLH1 expression status with very high sensitivity and specificity. This evidence concerns the gene MLH1 and inflammatory bowel disease.